NP2
AXP000200.1 · Viral vector gene therapy
- Platform
- HSV-1 (ICP4- ICP27-)
- Targets
- PENK
- Originator
- University of Michigan (David Fink)
- Sponsor
- Diamyd Medical
Names
Virus
- Role
- In vivo gene transfer
- Family
- Herpesviridae
- Virus
- herpes simplex virus 1 (NCBI Taxonomy 10298)
- Replication
- non replicating
- Modifications
- ICP4 and ICP27 deleted; human PENK under CMV IE promoter in both ICP4 loci
- Transgenes
- PENK
- Route
- intradermal
- Source
- evidence
Approvals
No regulatory approval recorded.
Clinical trials (3)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT05317195 | Nicotine Pharmacokinetics and Subjective Effects of Nicotine Pouch 1.0 Compared to Velo® Ice Cool and Zyn® Cool Mint Mini Dry in Healthy Smokers | Completed | 2022-03-15 | 2022-05-07 | 31 | Nicotine; Smoking | |
| NCT01291901 | NP2 Enkephalin For Treatment of Intractable Cancer Pain | Completed | Phase 2 | 2011-01 | 2012-07 | 33 | Intractable Pain; Neoplasms |
| NCT00804076 | Gene Transfer for Cancer Pain | Completed | Phase 1 | 2008-02 | 2010-11 | 10 | Cancer Pain |
Recent changes
No changes recorded in its trials yet.
Notes
Replication-defective HSV-1 vector deleted for ICP4 and ICP27 (and lacking ICP22/ICP47 promoters) carrying human preproenkephalin (PENK) under a CMV IE promoter in both ICP4 loci; injected intradermally in the painful dermatome. Phase 1 dose escalation in 10 patients with intractable cancer pain, NCT00804076, sponsored by Diamyd Incorporated (Ann Neurol 2011, PMID 21796661). Later taken forward by Periphagen; that transfer was not verified here.
How to cite
NP2 (AXP000200.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000200.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.